NARA Discovery
NARA Subscribed Scholarly Literature Discovery
Boolean search: climate AND coral · microplastic OR nanoplastic · plastic NOT freshwater · "marine heatwave"
Advanced Search
Topic searches article titles and abstracts. Starts a new search; publisher and year refine it.
Searches article titles and abstracts.
Accepts bare DOI, doi: prefix, or a doi.org URL.
Complete publisher name. Publisher imprints are grouped under their main publisher where applicable.
Exact match by full journal title or ISSN.
–
Refine Results Clear Filters
Collection
NARA Subscribed1
Publisher
Springer Nature1
Journal
Inflammopharmacology1
Publication Year
20231
Marta Mosca results 1 · Newest (Page 1/1, per page 25)
Export CSV Export RIS Export current results · up to 5,000 records
Author: Marta Mosca ×Clear All Filters
Search Results
Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effectsNARA Subscribed
Inflammopharmacology · 2023 · Vol. 31 · Issue 5 · Springer
Marco Di Battista; Laura Tavanti; Francesco Pistelli; Laura Carrozzi; Mattia Da Rio; Alessandra Rossi; Lorenzo Puccetti; Antonio Tavoni; Chiara Romei; Riccardo Morganti; Alessandra Della Rossa; Marta Mosca
Objective Nintedanib (NIN) is an antifibrotic drug approved to slow the progression of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-related interstitial lung disease (SSc-ILD). NIN can frequently cause gastrointestinal adverse effects. We aimed to investigate the NIN safety profile in a real life setting, comparing IPF and SSc-ILD patients and evaluating the strategies adopted to manage NIN adverse effects. Metho...
View Details View Full Text